A citation-based method for searching scientific literature

Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M Gadgeel, Toyoaki Hida, Dariusz M Kowalski, Manuel Cobo Dols, Diego L Cortinovis, Joseph Leach, Jonathan Polikoff, Carlos Barrios, Fairooz Kabbinavar, Osvaldo Arén Frontera, Filippo De Marinis, Hande Turna, Jong-Seok Lee, Marcus Ballinger, Marcin Kowanetz, Pei He, Daniel S Chen, Alan Sandler, David R Gandara. Lancet 2017
Times Cited: 2389



Drew M Pardoll. Nat Rev Cancer 2012
Times Cited: 6937




List of shared articles



Times cited

Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).
Corinne Faivre-Finn, David R Spigel, Suresh Senan, Corey Langer, Bradford A Perez, Mustafa Özgüroğlu, Davey Daniel, Augusto Villegas, David Vicente, Rina Hui,[...]. Lung Cancer 2021
1

Preclinical PET imaging with the novel human antibody 89Zr-DFO-REGN3504 sensitively detects PD-L1 expression in tumors and normal tissues.
Marcus P Kelly, Sosina Makonnen, Carlos Hickey, T Cody Arnold, Jason T Giurleo, Richard Tavaré, Makenzie Danton, Christian Granados, Ishita Chatterjee, Drew Dudgeon,[...]. J Immunother Cancer 2021
1

Immune Resistance in Lung Adenocarcinoma.
Magda Spella, Georgios T Stathopoulos. Cancers (Basel) 2021
5

Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer.
Monika Pradhan, Mathieu Chocry, Don L Gibbons, Boris Sepesi, Tina Cascone. Transl Lung Cancer Res 2021
5

Clinical impact of probiotics on the efficacy of anti-PD-1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting.
Kazuki Takada, Mototsugu Shimokawa, Shinkichi Takamori, Shinichiro Shimamatsu, Fumihiko Hirai, Tetsuzo Tagawa, Tatsuro Okamoto, Motoharu Hamatake, Yuko Tsuchiya-Kawano, Kohei Otsubo,[...]. Int J Cancer 2021
3

The Current Landscape of Immune Checkpoint Blockade in Glioblastoma.
Oluwatosin O Akintola, David A Reardon. Neurosurg Clin N Am 2021
0

Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade.
Romain Banchereau, Avantika S Chitre, Alexis Scherl, Thomas D Wu, Namrata S Patil, Patricia de Almeida, Edward E Kadel Iii, Shravan Madireddi, Amelia Au-Yeung, Chikara Takahashi,[...]. J Immunother Cancer 2021
3

Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis.
Shixue Chen, Zhibo Zhang, Xuan Zheng, Haitao Tao, Sujie Zhang, Junxun Ma, Zhefeng Liu, Jinliang Wang, Yuanyu Qian, Pengfei Cui,[...]. Front Oncol 2021
2

Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer.
Libin Zhang, Yanhui Chen, Han Wang, Zheyuan Xu, Yang Wang, Sixing Li, Jun Liu, Yun Chen, Hongli Luo, Lijia Wu,[...]. J Immunother Cancer 2021
0

Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC.
Michael J Grant, Roy S Herbst, Sarah B Goldberg. Nat Rev Clin Oncol 2021
4

Classification of Non-Small Cell Lung Cancer's Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint Blockade.
Alexander Chi, Xia He, Lin Hou, Nam P Nguyen, Guangying Zhu, Robert B Cameron, Jay M Lee. Cancers (Basel) 2021
1

Elevated expression of B7 homolog 4 is associated with disease progression in upper urinary tract urothelial carcinoma.
Tomoya Mizuno, Takao Kamai, Toyonori Tsuzuki, Daisaku Nishihara, Toshiki Kijima, Kyoko Arai, Ken-Ichiro Yoshida. Cancer Immunol Immunother 2021
1